# Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal

> **Open Intelligence Dossier** · First detected: 2026-09-28 16:40 UTC · Category: Business

## Executive Summary
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.

## Intelligence Brief
Recent coverage from BioSpace, FirstWord, simplywall.st, Endpoints News, OncLive, Reuters, and Fierce Biotech details that Merck and Daiichi Sankyo have voluntarily withdrawn their accelerated approval request and biologics license application for ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. This regulatory setback follows pushback from the United States Food and Drug Administration. The withdrawn application represents the second partnered cancer therapy application pulled by the companies, creating further challenges for their multi-billion dollar partnership. Media reports and analytical commentary emphasize the significance of this development for the companies&amp;#039; joint oncology pipeline.


Publications such as FirstWord and Fierce Biotech frame the withdrawal as another major obstacle following previous difficulties in their alliance. Financial commentary from simplywall.st questions the valuation implications for Daiichi Sankyo Company following the regulatory setback, while OncLive and Endpoints News provide specific clinical context regarding the target, identifying the therapy as a B7-H3 antibody-drug conjugate. Context provided across the reporting highlights that this application withdrawal directly impacts the broad partnership between the two pharmaceutical firms. The overarching alliance, valued in the coverage at four billion dollars, has faced repeated hurdles regarding regulatory approvals for its antibody-drug conjugate assets.


While prior coverage does not yet specify the exact nature of the regulatory feedback or the precise clinical data points that triggered the Food and Drug Administration pushback, the voluntary withdrawal effectively halts the current review process for this specific indication. Looking ahead, coverage does not yet specify whether the companies intend to resubmit the application or pursue alternative clinical pathways for ifinatamab deruxtecan. Observers and market participants will monitor upcoming corporate communications from Merck and Daiichi Sankyo for further details regarding the future of their shared oncology portfolio and the broader implications for their multi-billion dollar collaboration agreement following this dual setback.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaWFUZ1lUb3dVNk04akJhbXp3d0dCQl96NHl5MDFvYVFrSmkxRnFTREpDT2owaHd0bTVva0F4WHEwR1Y5Z2xHeWlZMExqN3hJM2hnT0ZVbWpvdUhnZmthaHlyX3czdUpRcHhmMmVHM0NobGxTRnJBY1ZManVTNTJWMnhXOTR6XzdmbTlUTzAxbHBER0NDZjZ6MVNzak54N2t6OUpWWkkySUVWQjdmQXVCZ1EwbVdrVHcwaHZr?oc=5) |
| FirstWord | Vital Signs: Twice bitten, thrice shy for Merck and Daiichi's ADC aspirations | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1VbVpBaTd6QmhFT0ZjZVdlZWVDSWoxeExuZWRMMkpUZ1R4M2stYmhzUmFXMGhabUI1ZnVnakY1SDJRZkpDSjFneUtSTldjcXY5WEJv?oc=5) |
| simplywall.st | Is Daiichi Sankyo Company (TSE:4568) Undervalued On Its FDA Filing Withdrawal? | [Source Link](https://news.google.com/rss/articles/CBMi5wFBVV95cUxQRUo2YVZiX2V0UkxRcTUwZ1JfY21hV0x0cWkzOEVpU0Q0LUZpODBVR05GNk4xQ2E5QXM0ODFSRGs0VHBpRFdDTTA4NU9HTF9Cc3BjNzVxd3Z6dXJrcVFEYkpaU0c2Rlk5TEtzaGN6MTNuSkVIclJvSmhUU1ZxUmREVld0NHpNVTMyVnZ6ZGJKZkQ4ZHBaOTY3cVVfWkItYlhHVUZOWGVDbmdCQUFXUjY2R0pyWDVkRWJ1S25zb0x4bWU0LUxNc3dfYjllb3VzVnlXTXJnWjk3d2FsZWRZUnFNOFBEUTRzN2PSAewBQVVfeXFMTjJkUUtJWlZyVnhCWS1SazVpYXJiOE5sVUV5cDJ4RVBVZnFiakhlVGlTN1ZUSVZVaDNHMm13VlpGcG1sb3lPdmpxX1hmbU8wVXd3VHhydC00S0U2RGkyOE02NTF5TG1WZFlOX00) |
| Endpoints News | Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxQRXhOX3F6Z0Q2LVk3TVkxeHBkVWN1dVp5YXRNalB6a0RSaEswMm9wUUxaM2lwd0I4VFdGb21UOW9rM2NSLU96eFFRVndUa2dsSGFSWDdER2picXhzLUtOMGlrM1YxSlN3bG5fSGFfa1BxZjZDZHJ1UHJtdmRab212NjBIYmNSNkwxOHRQUWJKNERrUQ?oc=5) |
| OncLive | Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVFhBNkVDc2JzdndSaUNzZTdyTXpNUXAwUkhGdVpxdXF3MFQtNm1rb0g3OFo2elFWUWZEUGRRY2tabTVNcUJTaDl1UFFTYzVHX2hWU3ZKSTBhTm1uT2lnMnQ4Tkl5NldEUUJ5a2thdndwcmZtQVd2bjJKcWVlcHdlZkZYRWxiQ3p3R054VFVMLXBIXzhDSmlTWWFvV2VVTXVfMGE5cHdiMWRYZjZFSnZHcHZObV9URWhQRURv?oc=5) |
| Reuters | Merck, Daiichi pull US application for second partnered cancer therapy | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxPY255UmdNQXFqU296Vi13YzlWX3Rnei1KX1NNZGQybU1hUVJUeUxxUU9oa0dvWk0zTzZXRk5xS01kVGhXWG1Ca000VVlZUlpJdVA1c1N2WEJCU1BGM3huRjlCZHZkQzEzdUdQLTZZS1Zka0ZRNi1Ya1lmekQ4M1Vnd2xOWTRUSldYdzZDMnFlQzc3dXdlWWV0WHJiNUZSUjZ0RDhXWFJfY3Q4TjhxVU8zczZGVHc?oc=5) |
| Fierce Biotech | Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxOa3RsYnRvVkpLUXJzSEpYMWNPWE0zckh1VUp2TjAxRzhFTlVUa0U0VXV3aTBGVUg3VTJEdVotNGxXNTYwZ1RwN3RKUmxlSjlTMFoxWVE1Zjh2a3dWNFFwMmVoZkxGRFd5MElWZ2ZBdERrelVVQVNLX1NQdm1NbnJXazBuclZMVEJFb3lzdkJDVVBLMTJLNm9UdVVVRmNaWFB4clRCeGk2NElZUUM0a2Nob3IyT0dqcVJ4NkdyS3J4Sk16bkRwUzZv?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-28/merck-daiichi-pull-lung-cancer-filing-after-fda-pushback-deals-another-blow-to*
